Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01783431 · ClinicalTrials.gov registry record · Phase 1

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

A Phase 1 study, sponsored by Medical University of South Carolina.

Terminated
Registry status
Phase 1
Development phase
1
Enrollment target

NCT01783431 is a Phase 1 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01783431, a Phase 1 study, was terminated before completion, sponsored by Medical University of South Carolina.

TERMINATED
Registry status
Phase 1
Development phase
1 participants
Enrollment target

Study Summary

This study is for subjects with a type of skin cancer called melanoma. The main purpose of this study is to examine the safety of the study drug (Poly-ICLC) in patients with your disease. The study team would like to know about any side effects a patient may have when given the study drug. Another goal of the study is to determine if combining dendritic cells and the study drug can be possibly used as a vaccine for your disease.

Interventions

  • DRUG Poly ICLC
  • PROCEDURE leukapheresis

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2012-10
Est. Completion 2013-11
Phase Phase 1

What the Registry Record Tells You About NCT01783431

The ClinicalTrials.gov registry entry for NCT01783431 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Poly ICLC is the first listed.

NCT01783431 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01783431 about?

NCT01783431 is a clinical study titled "Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells". This study is for subjects with a type of skin cancer called melanoma. The main purpose of this study is to examine the safety of the study drug (Poly-ICLC) in patients with your disease. The study team would like to know about any side effects a patient may have when given the study drug. Another g...

What is the current status of trial NCT01783431?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-10. Estimated completion is 2013-11.

What interventions are being tested in trial NCT01783431?

The interventions under investigation include: Poly ICLC (DRUG), leukapheresis (PROCEDURE).

Who is sponsoring clinical trial NCT01783431?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.